While it has long been appreciated that anti-tumor CD8 T cells are critical for control of cancer, these two studies are the first to show that MCC patients who have existing MCPyV oncoprotein-specific T cells at the start of therapy were more likely to respond. Here, CD8A is linked to cancer.